Pandaomics: An AI-Driven Platform for Therapeutic Target and Biomarker Discovery
February 2024
in “
Journal of Chemical Information and Modeling
”
PandaOmics AI-driven platform therapeutic target discovery biomarker discovery deep learning omics data analysis gene analysis pathway-level analysis compound identification target validation CDK20 hepatocellular carcinoma SIK2 anti-inflammation therapy anti-cancer therapy androgenetic alopecia aging ALS AI platform drug discovery hair loss baldness cancer inflammation Lou Gehrig's disease
TLDR PandaOmics uses AI to find new disease treatment targets and biomarkers.
PandaOmics is an AI-driven platform developed for therapeutic target and biomarker discovery, integrating deep learning with omics data analysis. It features a user-friendly interface and tools for gene and pathway-level analysis, compound identification, and target validation. The platform has demonstrated success in identifying novel therapeutic targets and compounds, such as CDK20 for hepatocellular carcinoma and SIK2 for anti-inflammation and anti-cancer therapy. PandaOmics is part of a broader AI-powered drug discovery ecosystem, enhancing efficiency and reducing costs in drug discovery processes. It has been applied in various studies, including those on androgenetic alopecia, aging, and ALS, showcasing its versatility and potential to accelerate drug discovery and provide new insights into disease mechanisms.
